US National Institutes of Health: Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 – Clinical Trial Not Allowed)

Activity Code: R61/R33 Exploratory/Developmental Phased Award

Funding Opportunity Announcement (FOA) Number: RFA-HD-19-015

The purpose of this funding opportunity announcement is to support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men and women that act prior to fertilisation. This opportunity aims to position innovative and validated methods for future clinical development

Funding & Duration

For the R61 phase, Direct Costs may not exceed USD $250,000 (approx. AUD $339,000) per year. For the R33 phase, Direct Costs may not exceed USD $500,000 (approx. AUD $677,000) per year.

The scope of the proposed project should determine the project period. The maximum project period of the combined R61 and R33 phases is up to 5 years with up to 2 years for the R61 phase and up to 3 years for the R33 phase. Applications with a project period of less than 5 years are encouraged where feasible.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Dates

Further Information

Need Help?

This entry was posted in Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding, Sciences and tagged . Bookmark the permalink.

Comments are closed.